Key clinical point: The combination of apatinib and etoposide proved to be a feasible treatment option for patients with triple-negative breast cancer (TNBC) who had failed ≥1 line of chemotherapy in the advanced setting.
Major finding: The median progression-free survival and overall survival were 6.0 and 24.5 months, respectively, with an objective response rate of 10.0% and a disease control rate of 62.5%. Overall, 95.0% of patients experienced adverse events (AE) of any grade, mostly grade 1 and 2. Hypertension (65.0%), nausea (47.5%), vomiting (42.5%), and hand-foot syndrome (32.5%) were the most common AE.
Study details: Findings are from a single-arm phase 2 study including 40 patients with advanced TNBC who had failed ≥1 line of chemotherapy and received oral apatinib plus oral etoposide.
Disclosures: This study was funded by National Cancer Fund Climbing Fund. The authors declared no conflicts of interest.
Source: Cao M et al. Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: A phase II trial. BMC Cancer. 2023;23:463 (May 19). doi: 10.1186/s12885-023-10768-8